References
- Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S–428S.
- Jang IK, Hursting Mi. When heparins promote thrombosis: reviewof heparin-induced thrombocytopenia. Circulation 2005; 111: 2671–2683.
- Anse11 J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. Thepharmacology and management of the vitamin K antagonists: the 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204S–233S.
- Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S–400S.
- Mann KG, Brummel K, Butenas S. What is all that thrombin for?J Thromb Haemost 2003; 1: 1504–1514.
- Eriksson BI, Borris L, Dahl OE et al. Oral, direct FXa inhibitionwith BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 4: 121–128.
- Depasse F, Busson J, Mnich J, Le Flem L, Gerotziafas GT, Samama MM. Effect of BAY 59–7939 — a novel, oral, direct factor Xa inhibitor-on clot bound factor Xa activity in vitro. J Thromb Haemost 2005; 3: P1104.
- Perzborn E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939— an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514–521.
- Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Multiple dose escalation study investigating the pharmacody-namics, safety, and pharmacokinetics of BAY 59-7939— an oral, direct Factor Xa inhibitor in healthy male subjects. Blood 2003; 102: 811A.
- Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939— an oral, direct Factor Xa inhibitor after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873–880.
- Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. Bay 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembo-lism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479–2486.
- Eriksson BI, Borris LC, Dahl OE et al. A once-daily, oral, direct Factor Xa inhibitor, Rivaroxaban (BAY 59-7939) for thrombo-prophylaxis after total hip replacement. J Am Heart Assoc 2006; 114: 2374–2381.
- Eriksson BI, Borris LC, Dahl OE et al. Dose-escalation study of rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007; 120: 685–693.
- Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007; 116: 180–187.
- Buller HR, Agnelli G. Once or twice daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies. Blood 2006; 108: abstract 572.
- Lassen MR, Turpie AGG, Rosencher N et al. Rivaroxaban — an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD 3 study. J Thomb Haemost 2007; 5: ISTH-07 abstract 0-S–006B.
- Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Influence of the duration of fondaparinux (Arixtra) prophylaxis in preventing venous thromboembolism following major orthopaedic surgery. J Thromb Haemost 2003; 1: 383–384.
- Bauer KA. Targeted inhibition of coagulation: oral agents show promise in phase III trials. J Thromb Haemost 2007; 5: 2175–2177.
- Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) — an oral, direct Factor Xa inhibitor — has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469–476.